Drugs / 3K3A-APC
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy4 trials | ||||||
| Phase 1 | NCT01660230 Comparator | Aug → Dec 2012 | — | ZZ Biotech, LLC | Completed | No outcome recorded |
| Phase 2 | NCT05039268 Comparator | Nov 2021 → Sep 2022 | amyotrophic lateral sclerosis | Macquarie University, Australia | Completed | No outcome recorded |
| Phase 2 | NCT02222714 Comparator | Oct 2014 → Apr 2017 | ischemic stroke | ZZ Biotech, LLC | Completed | No outcome recorded |
| Phase 3 | NCT05484154 Comparator | Oct 2024 → Jul 2026 | ischemic stroke | ZZ Biotech, LLC | Withdrawn | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 3K3A-APC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05039268 ↗ |
| Modality | Protein / enzyme biologic | “3K3A-APC, a Recombinant Variant of Human Activated Protein C (APC)” NCT01660230 ↗ |
| Route | Intravenous | “administered as an 20 mL IV infusion over 15 minutes” NCT01660230 ↗ |